DSGN
Design Therapeutics Inc
NASDAQ: DSGN · HEALTHCARE · BIOTECHNOLOGY
$13.41
+1.82% today
Updated 2026-05-05
Market cap
$822.56M
P/E ratio
—
P/S ratio
29,402.82x
EPS (TTM)
$-1.19
Dividend yield
—
52W range
$3 – $17
Volume
0.4M
Design Therapeutics Inc (DSGN) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | $-139000.00 | $-8.67M | $-29.38M | $-51.32M | $-58.56M | $-43.10M | $-54.36M |
| Capital expenditures | $76000.00 | $76000.00 | $1.54M | $918000.00 | $256000.00 | $340000.00 | $193000.00 |
| Depreciation | $5000.00 | $5000.00 | $129000.00 | $406000.00 | $537000.00 | $-5.60M | — |
| Stock-based comp | $0.00 | $450000.00 | $4.69M | $10.93M | $13.09M | $13.07M | $14.55M |
| Free cash flow | $-215000.00 | $-8.74M | $-30.91M | $-52.23M | $-58.82M | $-43.45M | $-54.55M |
| Investing cash flow | $-33.56M | $-33.56M | $-53.64M | $-220.99M | $52.54M | $43.95M | — |
| Financing cash flow | $196000.00 | $44.53M | $379.21M | $235000.00 | $724000.00 | $513000.00 | — |
| Dividends paid | — | — | — | — | — | — | — |
| Share repurchases | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — |
| Net change in cash | — | — | $296.19M | $-272.07M | — | — | — |